Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Core Viewpoint - Editas Medicine has experienced a significant decline in share price, losing approximately 37.1% over the past month, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1] Group 1: Earnings Estimates - Fresh estimates for Editas have trended upward in the past month, with the consensus estimate shifting by 16.77% [2] Group 2: VGM Scores - Editas currently holds a subpar Growth Score of D, a strong Momentum Score of A, and a poor Value Score of F, resulting in an overall aggregate VGM Score of F [3] Group 3: Outlook - The upward trend in estimates for Editas appears promising, with a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Group 4: Industry Performance - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where Pacira (PCRX) has gained 1.8% over the past month, reporting revenues of $187.25 million, a year-over-year increase of 3.3% [5] - Pacira is expected to report earnings of $0.61 per share for the current quarter, reflecting a year-over-year decline of 1.6%, with a Zacks Rank of 3 (Hold) and a VGM Score of B [6]